How Pharmaceutical Manufacturers Can Evaluate Alternative Coding Consumables

Pharmaceutical manufacturers explore alternative coding consumables for several practical reasons — improving performance on a particular substrate, consolidating suppliers, addressing a supply reliability concern, or benchmarking a long-standing incumbent. In each case, the evaluation must be structured enough to produce evidence a pharmaceutical quality function can act on. This article outlines a working framework.

Axion Group supports this kind of evaluation with pharmaceutical customers as a specialist supplier of candidate consumables.

Reasons manufacturers explore alternatives

Common triggers we see:

• A recurring print-quality issue that the incumbent supplier has not resolved
• An impending change in the primary substrate that may push the incumbent outside its intended application
• A supply-chain event (single-source concentration, long lead times, allocation)
• A budget review that asks whether the incumbent is still the best-fit product
• A strategic decision to qualify a second source for a critical consumable

The trigger shapes the evaluation. A performance-driven evaluation needs a tight test protocol; a supply-driven evaluation needs a broader shortlist and less depth per candidate.

Structured evaluation framework

A practical framework has five stages:

1. Requirement definition — what does the consumable need to do, on which substrates, at what line speed, through which downstream processes?
2. Shortlist — three to five candidates that on paper fit the requirement. Broader shortlists dilute the evaluation.
3. Documentation review — technical data, safety data, and supplier information reviewed by the customer's quality function.
4. Application trial — bench trial, then short production run, on the customer's actual substrate and coder.
5. Change-control decision — the trial evidence base is reviewed and a decision to add the alternative to the approved-consumable list is documented.

Each stage produces an artefact that supports the next. A shortlist without a written requirement produces an inconsistent trial; a trial without a documentation review can be reopened during an audit.

Trial parameters that matter

The trial parameters that most often catch application problems:

• Duration — long enough to see at least one shift change and, if practical, one substrate lot change.
• Sampling — samples pulled at defined intervals and retained for retest at 24 hours and at any documented ageing point.
• Test matrix — abrasion, solvent rub, and any relevant environmental exposure (heat seal, autoclave, warm-water rinse).
• Verification — samples read by the customer's own verification cameras or scanners at the customer's usual settings.
• Line environment — recorded, not assumed. Ambient temperature, humidity, and line speed are trial inputs.

A trial that omits one of these commonly re-surfaces the problem it was designed to prevent within three months of regular supply.

Documentation and QA sign-off

For pharmaceutical customers, the trial record is a working document with a downstream audience: the quality function, the auditor, and the next engineer to investigate a print issue. A useful trial record includes:

• Substrate supplier, grade, and lot reference
• Candidate consumable, lot, and cartridge references
• Line settings and environmental data
• Test results at initial cure and at 24 hours
• Verification-camera pass rates during the trial
• Observed deviations and their explanations
• The change-control decision and its rationale

None of this needs to be lengthy. A one-page trial record is more useful than a ten-page one that gets skimmed.

Working with a specialist supplier

A specialist supplier's role is to make the evaluation efficient. Practical asks:

• Provide technical documentation for the candidate against the customer's substrate profile.
• Supply representative trial quantities, not just a single cartridge.
• Support the trial with technical availability during working hours.
• Provide references or examples where the same product has been used in similar applications, without over-claiming.

Axion Group works this way with pharmaceutical customers. Product suitability for the customer's specific application remains subject to application testing under the customer's actual production conditions. When the trial concludes, the customer's approved-consumable list is stronger regardless of whether the alternative is adopted, because the incumbent's evidence base has been refreshed too.